Edition:
United States

Atossa Genetics Inc (ATOS.OQ)

ATOS.OQ on NASDAQ Stock Exchange Capital Market

0.53USD
23 Jun 2017
Change (% chg)

$0.01 (+2.69%)
Prev Close
$0.52
Open
$0.51
Day's High
$0.54
Day's Low
$0.50
Volume
69,456
Avg. Vol
36,360
52-wk High
$4.95
52-wk Low
$0.40

ATOS.OQ

Chart for ATOS.OQ

About

Atossa Genetics Inc. is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has... (more)
No analyst recommendations are available for ATOS.OQ.

Overall

Beta: 1.47
Market Cap(Mil.): $3.93
Shares Outstanding(Mil.): 7.41
Dividend: --
Yield (%): --

Financials

  ATOS.OQ Industry Sector
P/E (TTM): -- 38.61 19.01
EPS (TTM): -1.49 -- --
ROI: -216.72 8.77 -5.03
ROE: -216.72 13.56 -4.28

BRIEF-Atossa Genetics qtrly loss per share $0.45

* Atossa Genetics announces first quarter 2017 financial results and provides company update

May 11 2017

BRIEF-Atossa Genetics qtrly loss per basic common share $0.45

* "we are in the research and development phase and do not generate revenue"

May 11 2017

BRIEF-Atossa Genetics says second positive interim review on Phase 1 study of endoxifen may advance to final topical dosing level

* Atossa Genetics - second positive interim review on Phase 1 study of endoxifen from independent safety committee who concluded study may advance to final topical dosing level Source text for Eikon: Further company coverage:

May 10 2017

BRIEF-Atossa Genetics receives approval from institutional review board for continuation of its fulvestrant microcatheter phase 2 study

* Atossa Genetics receives approval from institutional review board for continuation of its fulvestrant microcatheter phase 2 study

May 09 2017

BRIEF-Atossa receives positive interim review from safety committee in Endoxifen study

* Atossa Genetics receives positive interim review from independent safety committee in phase 1 Endoxifen dose escalation study

Apr 20 2017

BRIEF-Atossa Genetics now sees public offering of up to 1.0 mln class A units

* Now sees public offering of up to 1.0 million class a units consisting common stock and warrants - sec filing

Mar 28 2017

BRIEF-Atossa Genetics files for public offering of up to 4 mln units

* Atossa Genetics - files for public offering of up to 4 million units

Mar 23 2017

BRIEF-Atossa Genetics amends qtrly loss to $0.04/shr in Form 10-Q amendment for qtr ended June 30, 2016

* Atossa Genetics Inc - amendment no. 1 to quarterly report on Form 10-Q amends company's quarterly report on Form 10-Q for quarter ended June 30, 2016

Mar 21 2017

More From Around the Web

Earnings vs. Estimates